Insider buying last 90 days
No open-market insider purchases were filed for SRRK in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every SRRK insider filing, plotted on the chart in Gekko.Open SRRK in Gekko
NASDAQ: SRRK
Scholar Rock (SRRK) Stock Analysis & Forecast
Sep 28 close
$49.13+0.50 (+1.0%)
Gekko Brief
AI summaryThis week's news centers on Scholar Rock's commercial and analyst momentum around its neuromuscular pipeline, including the recent ISEMBYLD product launch. Wedbush added SRRK to its Best Ideas List with a $70 price target and assigned an Outperform rating, while JP Morgan reiterated an Overweight rating and raised its price target from $63.00 to $70.00. Separate filings noted insider trust transfers by the COO and CEO, along with a new institutional position from Bank of America Corp DE.
Scholar Rock closed at $49.13, up 1%, with the price sitting between its 50-day average of $52.31 and 200-day average of $48.38. The GekkoIndex reads 65.3, placing the stock in the Accumulation zone, down 6.4 over five days. The current price sits 10.4% below the Gekko Fair Value of $54.85.
Scholar Rock's next earnings report is scheduled for 13 November 2026, 45 days out and beyond a typical 20-trading-day hold. Analyst sentiment across 16 firms remains heavily weighted toward buy ratings, with a consensus target of $70.44 implying 43.4% upside. Seasonality data shows the next 20 trading days have averaged a 52% gain over 5 years, though only 3 of those years were positive. No insider, Congress, or unusual options activity appears in the current windows.
Written by AI and checked automatically against the figures on this page. Generated Sep 29, 2026 from the data above.
Scholar Rock price vs fair value
Close $49.13200-day averageGekko Fair Value $54.85
Scholar Rock quick facts
- Market cap
- $5.89B
- P/E ratio
- —
- Forward P/E
- —
- EPS, TTM
- −$3.31
- Revenue, TTM
- $0
- Profit margin
- 0%
- Dividend yield
- —
- Beta
- 0.68
- Volume
- 1.57M avg 2.18M
- 1-year return
- +42.4%
- Typical daily move
- ±5.9%
- Typical 20-day move
- ±12.4%
- 50-day average
- $52.31
- 200-day average
- $48.38
- Next earnings
- Nov 13 before open
- Shares outstanding
- 121.8M
Scholar Rock swing-trade checklist
Scholar Rock scores 4 supportive, 1 mixed and 0 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
4 supportive1 mixed0 headwinds
- Trendmixed
Averages disagree
Close $49.13 sits between the 50-day ($52.31) and 200-day ($48.38) averages, or the averages disagree.
See the chart - GekkoIndexsupportive
65.3, Accumulation
Reading 65.3 is in the Accumulation zone.
See the GekkoIndex - Fair valuesupportive
10.4% below
Price is 10.4% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings risksupportive
Reports in 45 days
Next report Nov 13, 2026, 45 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+52.0% on average
From this point in the calendar, the next 20 trading days averaged +52% over 5 years, rising in 3 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Scholar Rock stock chart and price history
Scholar Rock closed at $49.13 on Sep 28, 2026, +42.4% over the past year, inside a 52-week range of $27.07 to $61.76.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −17.1%
- 3 months
- −10.6%
- 6 months
- +15.3%
- 1 year
- +42.4%
The full SRRK chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open SRRK in Gekko
Follow Scholar Rock through every session
Put SRRK on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track SRRK in GekkoFree for 7 days. No credit card required.
About Scholar Rock
Scholar Rock is a biopharmaceutical company focused on developing treatments for serious diseases by working with protein growth factor signaling pathways. Its most advanced program is apitegromab, a candidate that blocks the activation of latent myostatin and has completed Phase 3 trials for spinal muscular atrophy. A second program, SRK-181, is in Phase 1 testing for cancers that have grown resistant to standard checkpoint inhibitor drugs such as anti-PD-1 or anti-PD-L1 antibodies.
Beyond these two programs, the company maintains a broader pipeline aimed at neuromuscular disease, cancer, and fibrotic conditions. It has also formed a research collaboration with Gilead Sciences to find and develop inhibitors that target the activation of transforming growth factor beta, with an eye toward treating fibrotic diseases.
Scholar Rock was founded in 2012 and is headquartered in Cambridge, Massachusetts. Its shares trade on the NASDAQ under the ticker SRRK.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Biotechnology
- Website
- scholarrock.com
Scholar Rock GekkoIndex: the smart money zone
Scholar Rock’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 65.3, in the Accumulation zone, down 6.4 points over five sessions.
65.3Accumulation
Down 6.4 points over five sessions, from the Buying zone.
Reading for Sep 28, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 43 | +5.8% | +7.2% | ||
| Accumulation (current zone) | 212 | +7.0% | +18.1% | ||
| Neutral | 387 | −0.6% | +4.8% | ||
| Distribution | 28 | +3.2% | +1.0% | ||
| Selling | 2 | Too few readings yet | |||
Average SRRK share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.3% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
See every daily GekkoIndex reading plotted over the SRRK price, zone by zone.Track SRRK in Gekko
Is Scholar Rock stock overvalued? Gekko Fair Value
Scholar Rock trades 10.4% below Gekko Fair Value of $54.85, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Scholar Rock shares are worth, recalculated every trading day.
$54.85
Gekko Fair Value, Sep 26, 2026
10.4% Undervalued
Gekko Fair Value on every chart, with the gap to price updating daily.Open SRRK in Gekko
Scholar Rock insider and Congress trading
No open-market insider purchases were filed for Scholar Rock, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in SRRK were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for SRRK, plotted on the chart in Gekko.Open SRRK in Gekko
Hedge funds and billionaires quarter ended Sep 30
0of the funds Gekko tracks hold SRRK.
0added0opened0trimmed1sold out
Which funds are on each side, name by name.Unlock in Gekko
Scholar Rock earnings: next date and track record
Scholar Rock reports on Nov 13, 2026, before the open (45 days away), and beat the EPS estimate in 2 of its last 8 reports.
Next earnings report
Nov 13, 2026
Expected before the open, 45 days away
- EPS estimate
- −$0.86
- Revenue estimate
- $733K
2 of 8reports beat the EPS estimate
±8.5%average move across the report
5 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Aug 6, 2026 AI summary
- What they said
- Scholar Rock is preparing for the U.S. launch of apitegromab (SMA therapy) with a PDUFA date of September 30, 2026. The BLA was accepted in April after resubmission with two fill/finish facilities, providing dual approval pathways. Commercial teams are launch-ready, vials from both facilities are awaiting packaging upon approval. European MAA is progressing pending FDA inspection classification of Catalent Indiana.
- Guidance
- Management targets U.S. launch of apitegromab by September 30, 2026 PDUFA date, with teams ready to launch at any time prior. European approval timing guidance will be updated pending regulatory alignment on fill/finish facility inclusion.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 6, 2026 | −$0.84 est −$0.84 | — est $70K | +10.5% |
| May 7, 2026 | −$0.83 est −$0.82 | — est $5.00M | +2.7% |
| Mar 3, 2026 | −$0.88 est −$0.88 | — est $1.83M | +9.1% |
| Nov 14, 2025 | −$0.90 est −$0.84 | — est $50K | +21.3% |
| Aug 6, 2025 | −$0.98 est −$0.66 | — est $56K | −15.1% |
| May 14, 2025 | −$0.67 est −$0.63 | — | −1.8% |
| Feb 27, 2025 | −$0.60 est −$0.60 | — | +4.9% |
| Nov 12, 2024 | −$0.66 est −$0.60 | — | −2.7% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Scholar Rock stock forecast and analyst price targets
Analysts’ average 12-month price target for Scholar Rock is $70.44, +43.4% from the last close, from 16 firms rating the stock in the last 90 days.
$70.44consensus 12-month target, +43.4% from the last close
Now $49.13Avg $70.44
Low $58High $84
Each firm’s latest rating in the last 90 days: 16 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 25 | Piper Sandler | $75 | +52.7% |
| Sep 25 | Wedbush | $70 | +42.5% |
| Sep 24 | Truist Financial | $77 | +56.7% |
| Sep 21 | J.P. Morgan | $70 | +42.5% |
| Sep 16 | Leerink Partners | $65 | +32.3% |
+18.1%average 20-day move after past Accumulation readings
+52.0%average move over the next 20 trading days in the last 5 years
±5.9%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Scholar Rock seasonality: the next 20 trading days
Over the next 20 trading days from Sep 29, Scholar Rock averaged +52.0% across the last 5 years, rising in 3 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +0.9% | 3 of 5 |
| Next 10 trading days | +39.1% | 3 of 5 |
| Next 15 trading days | +43.2% | 3 of 5 |
| Next 20 trading days | +52.0% | 3 of 5 |
| Next 30 trading days | +53.9% | 4 of 5 |
For scale, SRRK’s typical 20-trading-day move in either direction is about 12.4%.
Scholar Rock market cap and key statistics
Scholar Rock’s market cap is $5.89B and revenue of $0 over the last twelve months.
Valuation
- Market cap
- $5.89B
- EPS, TTM
- −$3.31
- Gekko Fair Value
- $54.85
Trading
- Volume
- 1.57M
- Avg volume, 20 days
- 2.18M
- 52-week high
- $61.76
- 52-week low
- $27.07
- Shares outstanding
- 121.8M
Financials
- Revenue, TTM
- $0
- Profit margin
- 0%
- Return on equity
- -167.8%
- Quarterly earnings growth, YoY
- 0.0%
Risk and income
- Beta
- 0.68
- Typical daily move
- ±5.9%
- Typical 20-day move
- ±12.4%
Scholar Rock stock news this week
Coverage of Scholar Rock this week reads positive: 4 positive, 3 neutral and 0 negative headlines.
- Form 4 Scholar Rock Holding Corp For: 26 September By Investing.comInvesting.com Nigeria, Sep 27
- No common shares appear in Scholar Rock (SRRK) COO Keith Woods’s reported position after a gift to a trust.Stock Titan, Sep 25
- Scholar Rock added to Wedbush's Best Ideas ListSeeking Alpha, Sep 25
- Wedbush Rates Scholar Rock (SRRK) Outperform Amid Attractive Price-to-Sales OpportunityGuruFocus, Sep 25
- No payment changed hands when Scholar Rock (SRRK) CEO David Hallal transferred 36,652 shares to a family trust.Stock Titan, Sep 24
- SRRK Maintains Overweight Rating by JP Morgan -- Price Target RaGuruFocus, Sep 22
Scholar Rock peers
Scholar Rock’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| AMGNAmgen | Neutral | 24.4% below |
| GILDGilead Sciences | Neutral | 6.9% above |
| MRNAModerna | Neutral | 73.2% above |
| NTRANatera | Distribution | 25.1% above |
| IQVIQVIA | Neutral | 14.2% above |
| UTHRUnited Therapeutics | Accumulation | 23.6% below |
A peer links to its own page where one exists.
Scholar Rock stock FAQ
What is Scholar Rock’s market cap?
Scholar Rock’s market cap is $5.89B at the Sep 28, 2026 close of $49.13, with 121.8M shares outstanding.
What is the Scholar Rock stock forecast?
The consensus analyst 12-month price target for Scholar Rock is $70.44, +43.4% from the last close. Of the 16 firms that rated the stock in the last 90 days, 15 rate it a buy, 1 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Scholar Rock stock overvalued or undervalued?
On Gekko’s estimate Scholar Rock is undervalued: the Sep 28, 2026 close of $49.13 is 10.4% below Gekko Fair Value of $54.85. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Scholar Rock report earnings next?
Scholar Rock is expected to report on Nov 13, 2026, before the market opens (45 days away). Analysts expect earnings of −$0.86 per share on revenue of $733K. Scholar Rock beat the earnings estimate in 2 of its last 8 reports, moving 8.5% on average across the report.
What is Scholar Rock’s 52-week high and low?
Scholar Rock’s 52-week high is $61.76 and its 52-week low is $27.07; it closed at $49.13 on Sep 28, 2026, +42.4% over the past year.
Is Scholar Rock stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 4 of the 5 items with data read as supportive (gekkoindex, fair value, earnings risk and seasonality), 1 as mixed (trend). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Scholar Rock the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,380 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.